A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval.

Daiichi Sankyo cut back Enhertu's U.S. sales estimate for its 2023 fiscal year but dialed up the ADC's global forecast. ... If approved, Dato-DXd’s lung cancer indication would likely be limited.

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...